Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

Press/Media

Period	9 Mar 2025

Media coverage

Title	Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
Media name/outlet	Patient Care Online
Country/Territory	United States
Date	9/03/25
URL	ct.moreover.com/?a=56205909118&p=1gw&v=1&x=rTv3r7N7uwoLVKQ3HfCtMQ
Persons	Emma Guttman